Response to therapy in a cohort of patients with late-onset multiple sclerosis
{{output}}
Background and objectives: Late-onset MS (LOMS, symptom onset after age 50) remains underrepresented in clinical trials, leading to a gap in knowledge about the efficacy of disease-modifying therapies (DMTs). This study aims to e... ...
